Hodgkin’s Disease
Pathophysiology
The role of cytokines in classical Hodgkin lymphoma.
Skinnider BF, Mak TW.
Blood. 2002;99:4283-4297.
Description: Review of the role of cytokines in the pathogenesis of HL.
PubMed citation number: 12036854
Characteristics of Hodgkin's lymphoma after infectious mononucleosis.
Hjalgrim H, Askling J, Rostgaard K, et al.
N Engl J Med. 2003;349:1324-1332.
Description: A population-based cohort study comparing the prevalence of Hodgkin lymphoma in patients previously identified as being infected with Epstein-Barr virus (EBV) as compared to patients who were not infected with EBV. Concluded that a causal association between EBV infection and EBV + Hodgkin lymphoma is likely in young adults.
PubMed citation number: 14523140
Diagnosis/Staging
Report of the committee on Hodgkin’s Disease staging classification.
Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M.
Cancer Res. 1971;31:1860-1861.
Description: Publication that established the Ann Arbor staging system.
PubMed citation number: 5121694
FDG-PET in the clinical management of Hodgkin lymphoma.
Hutchings M, Eigtved AI, Specht L.
Crit Rev Oncol Hematol. 2004;52:19-32.
Description: Recent review of the evidence supporting PET staging for HL.
PubMed citation number: 15363464
Treatment
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
Canellos GP, Anderson JR, Propert KJ, et al.
N Engl J Med. 1992;327:1478-1484.
Description: Multicenter randomized controlled trial (RCT) that established that 5-year overall survival is equivalent with ABVD and MOPP/ABVD, and inferior with MOPP alone. Myelotoxicity was less with ABVD alone.
PubMed citation number: 1383821
Hodgkin's disease: complications of therapy and excess mortality.
Hoppe RT.
Ann Oncol. 1997;8:115-118.
Description: Single-center, retrospective case series of all cause mortality in Hodgkin lymphoma patients. Demonstrated excess non-HL mortality, particularly beyond 15 years of follow-up.
PubMed citation number: 9187444
Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients: International Hodgkin's Disease Collaborative Group.
Specht L, Gray RG, Clarke MJ, Peto R.
J Clin Oncol. 1998;16:830-843.
Description: Meta-analysis of 21 trials of extended field radiation versus involved field radiation, radiation, and radiation plus chemotherapy for early-stage Hodgkin lymphoma.
PubMed citation number: 9508163
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Schmitz N, Pfistner B, Sextro M, et al.
Lancet. 2002;359:2065-2071.
Description: RCT of salvage chemotherapy versus salvage chemotherapy + high-dose therapy and stem cell transplantation for relapse Hodgkin lymphoma. Reported superior freedom from treatment failure with transplantation for patients with chemosensitive disease.
PubMed citation number: 12086759
Involved-field radiotherapy for advanced Hodgkin's lymphoma.
Aleman BM, Raemaekers JM, Tirelli U, et al.
N Engl J Med. 2003;348:2396-2406.
Description: Multicenter RCT. Demonstrated that involved field radiation therapy (IFRT) does not affect outcome in patients with advanced-stage Hodgkin lymphoma who achieve complete remission after MOPP-ABV chemotherapy.
PubMed citation number: 12802025
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V, Franklin J, Pfreundschuh M, et al.
N Engl J Med. 2003;348:2386-2395.
Description: RCT comparing COPP/ABVD versus BEACOPP versus increased-dose BEACOPP for patients with stage IIb, III, or IV Hodgkin lymphoma. Reported improved 5-year overall survival for patients treated with increased-dose BEACOPP. This regimen was more myelotoxic.
PubMed citation number: 12802024
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s Lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group.
Engert A, Schiller P, Josting A, et al.
J Clin Oncol. 2003;21:3601-3608.
Description: Multicenter RCT of COPP/ABVD + EFRT versus COPP/ABVD + IFRT for early-stage HL. Similar efficacy and less toxicity was reported with the use of IFRT.
PubMed citation number: 12913100
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM, Gospodarowicz MK, Connors JM, et al.
J Clin Oncol. 2005;23:4634-4642.
Description: Multicenter RCT of ABVD versus ABVD + radiation for patients with limited-stage HL. Reported that 5-year freedom from disease progression was superior in patients who received radiation; however, no differences in 5-year event-free survival or overall survival were detected.
PubMed citation number: 15837968
Prognosis
A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease.
Hasenclever D, Diehl V.
N Engl J Med. 1998;339:1506-1514.
Description: Retrospective multicenter study that used cox-proportional modeling to develop a 7-item prognostic score for advanced-stage Hodgkin lymphoma.
PubMed citation number: 9819449
Review
Hodgkin's lymphoma: evolving concepts with implications for practice.
Meyer RM, Ambinder RF, Stroobants S.
Hematology (Am Soc Hematol Educ Program). 2004;184-202.
Description: Recent review of the pathogenesis, diagnosis, and treatment of HL.
PubMed citation number: 15561683